frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 12 September 2023
DOI 10.3389/fimmu.2023.1283355

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Audray K. Harris
harrsiau@mail.nih.gov

RECEIVED 25 August 2023
ACCEPTED 30 August 2023
PUBLISHED 12 September 2023

CITATION
Myers ML, Gallagher JR, Woolfork D'MD, Stradtmann-Carvalho RK, Maldonado-Puga S, Bock KW, Boyoglu-Barnum S, Syeda H, Creanga A, Alves DA, Kanekiyo M and Harris AK (2023) Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus. *Front. Immunol.* 14:1283355. doi: 10.3389/fimmu.2023.1283355

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

Mallory L. Myers[1], John R. Gallagher[1], De'Marcus D. Woolfork[1], Regan K. Stradtmann-Carvalho[1], Samantha Maldonado-Puga[1], Kevin W. Bock[2], Seyhan Boyoglu-Barnum[3], Hubza Syeda[3], Adrian Creanga[3], Derron A. Alves[2], Masaru Kanekiyo[3] and Audray K. Harris[1*]

[1]Structural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States, [2]Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States, [3]Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

KEYWORDS

influenza B, MF59 adjuvant, commercial vaccine, challenge, Yamagata lineage

A Corrigendum on

Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

by Myers ML, Gallagher JR, Woolfork D'MD, Stradtmann-Carvalho RK, Maldonado-Puga S, Bock KW, Boyoglu-Barnum S, Syeda H, Creanga A, Alves DA, Kanekiyo M and Harris AK (2022). *Front. Immunol.* 13:1002286. doi: 10.3389/fimmu.2022.1002286

In the published article, there was an error in the legend for Figure 4 as published. "quadrivalent and trivalent vaccinations" should have been "vaccinations" and "Flucelvax (Q) (green)" removed. The corrected legend appears below.

"Measuring viral titers in the nasal turbinates and lungs of mice following vaccinations and subsequent challenge with Yamagata-lineage influenza B virus. **(A)** Immunization and challenge schedule with prime and boost (day 0 and 21), intranasal challenge (day 42), and bleeds (day 0, 14, and 35). On day 45 mice were euthanized for the harvesting of lungs and nasal turbinates. **(B)** Viral levels in the nasal turbinates of mice as measured by tissue culture infectious dose 50 (TCID50). **(C)** Viral levels in the left lung of mice as measured by TCID50. P-values are indicated for the significance of differences and NS denotes no statistical difference. Vaccines were Fluad (T) (blue) and Fluzone (T) (red) with saline (black) and non-infected controls (white). Yamagata-lineage challenge virus was mouse-adapted B/Florida/04/2006."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

10.3389/fimmu.2023.1283355



FIGURE 4
Measuring viral titers in the nasal turbinates and lungs of mice following vaccinations and subsequent challenge with Yamagata-lineage influenza B virus. **(A)** Immunization and challenge schedule with prime and boost (day 0 and 21), intranasal challenge (day 42), and bleeds (day 0, 14, and 35). On day 45 mice were euthanized for the harvesting of lungs and nasal turbinates. **(B)** Viral levels in the nasal turbinates of mice as measured by tissue culture infectious dose 50 (TCID50). **(C)** Viral levels in the left lung of mice as measured by TCID50. P-values are indicated for the significance of differences and NS denotes no statistical difference. Vaccines were Fluad (T) (blue) and Fluzone (T) (red) with saline (black) and non-infected controls (white). Yamagata-lineage challenge virus was mouse-adapted B/Florida/04/2006.

Publisher's note